Core Points - The company announced that its board member and senior vice president, Yu Jiangtao, holds 525,000 shares, accounting for 0.11% of total shares, and plans to reduce his holdings by up to 130,000 shares (0.03%) through centralized bidding from December 17, 2025, to March 16, 2026 [1] - The company’s board secretary and vice president, Xing Xiaoliang, holds 352,500 shares, representing 0.07% of total shares, and intends to reduce his holdings by up to 88,000 shares (0.02%) during the same period [1]

证券代码：300109 证券简称：新开源 公告编号：2025-040 博爱新开源医疗科技集团股份有限公司 关于部分董事、高级管理人员股份减持计划的预披露公告 董事、高级管理人员于江涛先生、高级管理人员邢小亮先生保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 截至本公告日持有博爱新开源医疗科技集团股份有限公司（以下简称"公司" 或"本公司"）股份 525,000 股（占本公司总股本比例 0.11%）的董事、高级管 理人员于江涛先生计划在本公告披露之日起 15 个交易日后的 3 个月内（2025 年 12 月 17 日至 2026 年 03 月 16 日，但窗口期不减持）以集中竞价交易方式减持 公司股份不超过（含）130,000 股（占公司总股本的比例不超过 0.03%）。 截至本公告日持有公司股份 352,500 股（占本公司总股本比例 0.07%）的高 级管理人员邢小亮先生计划在本公告披露之日起15个交易日后的3个月内（2025 年 12 月 17 日至 2026 年 03 月 16 日，但窗口 ...

Market Overview - As of 10:31 AM today, the Shanghai Composite Index is at 3876.57 points, above the six-month moving average, with an increase of 1.04% [1] - The total trading volume of A-shares today is 853.41 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 382 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Tonghe Technology (300491) with a deviation rate of 9.12% and a price increase of 10.01% [1] - Xunxing Co., Ltd. (002098) with a deviation rate of 9.03% and a price increase of 10.04% [1] - Laimu Co., Ltd. (603633) with a deviation rate of 7.04% and a price increase of 7.90% [1] Additional Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Longyuan Technology (not specified) and Newcapec (not specified) with minor deviations [1] - Other stocks with notable performance include: - Hongbai New Materials (605366) with a deviation rate of 6.77% and a price increase of 7.26% [1] - Kecuan Technology (603052) with a deviation rate of 5.50% and a price increase of 10.00% [1]

Group 1 - The core viewpoint of the news is that Xin Kai Yuan's stock performance and financing activities indicate a high level of market interest, despite a decline in revenue and profit [1][2]. - On November 17, Xin Kai Yuan's stock price decreased by 0.71%, with a trading volume of 179 million yuan. The net financing buy was negative at -20.50 million yuan, indicating more selling than buying in the financing market [1]. - As of November 17, the total financing and securities lending balance for Xin Kai Yuan was 803 million yuan, with the financing balance accounting for 9.10% of the circulating market value, which is above the 80th percentile of the past year [1]. Group 2 - Xin Kai Yuan Medical Technology Group Co., Ltd. was established on March 13, 2003, and listed on August 25, 2010. The company specializes in the research, production, and sales of high-value pharmaceutical excipients and diagnostic services [2]. - The main revenue sources for Xin Kai Yuan include PVP products (39.57%), PVPK30 powder (28.35%), and other diagnostic services, with a total revenue of 951 million yuan for the first nine months of 2025, reflecting a year-on-year decrease of 14.36% [2]. - The company reported a net profit of 201 million yuan for the same period, which is a 35.39% decrease compared to the previous year [2]. Group 3 - Xin Kai Yuan has distributed a total of 900 million yuan in dividends since its A-share listing, with 607 million yuan distributed over the past three years [3].

Market Overview - The precision medicine sector experienced a slight decline of 0.01% on November 12, with Guomai Technology leading the drop [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance - Zhongyuan Xiehe saw a significant increase of 10.00%, closing at 28.61 with a trading volume of 311,400 shares and a transaction value of 857 million [1] - Yangpu Medical and Beilu Pharmaceutical also reported gains of 4.13% and 2.96%, respectively [1] - Guomai Technology, on the other hand, declined by 3.17%, closing at 11.62 [2] Capital Flow - The precision medicine sector saw a net inflow of 311 million from institutional investors, while retail investors experienced a net outflow of 318 million [2] - Major stocks like Zhongyuan Xiehe and Yaoming Kangde attracted significant institutional investment, with net inflows of 1.941 billion and 76.27 million, respectively [3] Individual Stock Highlights - Zhongyuan Xiehe had a net institutional inflow of 1.941 billion, accounting for 22.65% of its trading volume, while retail investors withdrew 932 million [3] - Yaoming Kangde also saw a net institutional inflow of 76.27 million, with retail investors withdrawing 430 million [3] - Other notable stocks with positive institutional inflows include Beilu Pharmaceutical and Yangpu Medical, with net inflows of 33.03 million and 26.56 million, respectively [3]

Core Insights - New Source's stock price increased by 2.12% on November 7, reaching 18.31 CNY per share, with a total market capitalization of 8.9 billion CNY [1] - The company has seen a year-to-date stock price increase of 16.62%, with a 10.37% rise over the last five trading days [1] Financial Performance - For the period from January to September 2025, New Source reported revenue of 951 million CNY, a year-on-year decrease of 14.36%, and a net profit attributable to shareholders of 201 million CNY, down 35.39% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 900 million CNY, with 607 million CNY distributed over the last three years [3] Business Overview - New Source, established on March 13, 2003, and listed on August 25, 2010, is located in Jiaozuo City, Henan Province, and specializes in the R&D, production, and sales of PVP series products, high-value pharmaceutical excipients, and in vitro diagnostic services [1] - The company's revenue composition includes: 39.57% from other PVP products, 28.35% from PVPK30 powder, 14.80% from the Oruisi series, and smaller contributions from precision medical services and early cancer diagnosis [1] Shareholder Information - As of October 20, New Source had 19,900 shareholders, a decrease of 1.49% from the previous period, with an average of 22,604 circulating shares per shareholder, an increase of 1.51% [2] Industry Classification - New Source belongs to the Shenwan industry classification of basic chemicals, specifically in the category of other chemical products, and is associated with concepts such as cancer treatment, innovative drugs, medical devices, biomedicine, and in vitro diagnostics [2]

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Group 1 - The core viewpoint highlights the positive performance of the gaming and cultural media sector, with the CSI Hong Kong-Shanghai Gaming and Cultural Media Index showing resilience and potential for continued growth [1][2] - MiniMax has released a new text model, MiniMax-M2, which ranks among the top five globally in the Artificial Analysis (AA) evaluation, marking a significant achievement for Chinese open-source models [1] - The performance of MiniMax-M2 surpasses Google's Claude Sonnet 4.5 in speed by nearly double, while being priced at only 8% of its cost [1] Group 2 - Huayuan Securities emphasizes the ongoing strong performance of the gaming sector driven by high-quality products, suggesting continued focus on this area [2] - The AI-driven content creation industry is expected to experience high growth due to supply and demand dynamics, with a recommendation to monitor advancements in AI technology and application [2] - The CSI Hong Kong-Shanghai Gaming and Cultural Media Index includes 50 listed companies from various sectors, reflecting the overall performance of the gaming and cultural media theme in the markets [2]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with all board members assuming legal responsibility for any misrepresentation or omissions [2][3]. Financial Data - The third-quarter financial report has not been audited [3][7]. - There are no adjustments or restatements of previous accounting data [3]. - The company does not have any non-recurring gains or losses [3]. Shareholder Information - The company has reported changes in the number of shareholders and the status of restricted shares [5]. Other Important Matters - A subsidiary has received approval for clinical trials of a new drug for advanced solid tumors [5]. - The company plans to distribute cash dividends amounting to 121,175,001.25 yuan, with a record date of July 9, 2025 [5]. - The company is investing a total of 50 million yuan in Huadao (Shanghai) Biomedicine Co., Ltd. to enhance its competitive advantage in precision medicine [6].

Core Viewpoint - New Source (300109.SZ) reported a decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 951 million yuan, a year-on-year decrease of 14.36% [1] - The net profit attributable to shareholders was 201 million yuan, reflecting a year-on-year decrease of 35.39% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 182 million yuan, down 43.50% year-on-year [1] - Basic earnings per share stood at 0.41 yuan [1]